FINWIRES · TerminalLIVE
FINWIRES

B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63

By

Capricor Therapeutics (CAPR) has an average rating of buy and mean price target of $45.20, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

UBS Upgrades Cameco to Buy From Neutral, CA$166 Price Target

UBS Upgrades Cameco to Buy From Neutral, CA$166 Price Target

$CCJ
Research

BofA Securities Initiates Coverage on Clean Harbors With Buy Rating, $360 Price Target

Clean Harbors (CLH) has an average rating of overweight and mean price target of $332.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $302.77, Change: $-0.98, Percent Change: -0.32%

$CLH
Research

RBC Raises Price Target on Tenet Healthcare to $283 From $236, Keeps Outperform Rating

Tenet Healthcare (THC) has an average rating of buy and mean price target of $255, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$THC